マイクロサテライト不安定性またはミスマッチ修復欠損と呼ばれる特定の DNA 変異を持つ癌患者における HRO761 単独または併用療法の研究。

基本情報

NCT ID: NCT05838768
ステータス: 募集中
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 327
治験依頼者名: Novartis

概要

The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to treat those cancers.

対象疾患

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

介入

HRO761(DRUG)

pembrolizumab(BIOLOGICAL)

irinotecan(DRUG)

依頼者（Sponsor）

ノバルティスファーマ株式会社(INDUSTRY)